These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales. Cervino I, Gonzalez D, Nastro M, Vega J, Reyes AP, Buriano G, Vay C, Famiglietti A, Rodriguez CH. J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763 [Abstract] [Full Text] [Related]
18. [Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas]. Honderlick P, Gravisse J, Dardelle D, Cahen P. Pathol Biol (Paris); 2007 Dec 08; 55(10):475-7. PubMed ID: 17904768 [Abstract] [Full Text] [Related]
19. Microbiology and pharmacology of aztreonam. Duma RJ. Urology; 1988 Jun 08; 31(6 Suppl):9-13. PubMed ID: 3287750 [Abstract] [Full Text] [Related]
20. [Aztreonam: monocenter microbiological study with prevention experience in surgery]. Malcangi A, Pesce S, Vitale M, Martinetto P. G Batteriol Virol Immunol; 1987 Jun 08; 80(1-12):237-51. PubMed ID: 3509031 [Abstract] [Full Text] [Related] Page: [Next] [New Search]